Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination with Bevacizumab in Subjects with Advanced Colorectal Cancer

Next Previous
X
Search
Trial Profile

Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination with Bevacizumab in Subjects with Advanced Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 363 (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 23 Sep 2024 New trial record
    • 17 Sep 2024 According to Innovent Biologics , data of this trial is presented at the 2024 ESMO Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top